|
|
|
|
|
|
|
|
|
12.08.26 - 23:42
|
Singer Vehicle Founder on Louis Vuitton Partnership (Bloomberg)
|
|
|
In a groundbreaking collaboration, luxury fashion house Louis Vuitton and high-end automotive restoration company Singer have teamed up to create custom Porsche cars. This marks a first for both brands, as Louis Vuitton has never engaged in co-branding before, and Singer has not previously partnered on such a project. Rob Dickinson & Mazen Fawaz speak with Romaine Bostick on "The Close." (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
12.08.26 - 18:03
|
Eurofins Scientific: Director/PDMR Shareholding (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
Analytical Bioventures S.C.A (RCS B89265)
23, Val Fleuri, L-1526 Luxembourg
2.
Reason for the notification
a)
Position / status
Analytical Bioventures S.C.A. is a company controlled by Eurofins Scientific S.E., CEO Dr. Gilles Martin
b)
Initial notification / amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Eurofins Scientific S.E.
b)
LEI
529900JEHFM47DYY3...
|
|
|
|
|
|
|
|
|
|
|
12.08.26 - 17:01
|
Ouster Aktie: KI-Boom sorgt für kräftiges Wachstum (Aktiencheck)
|
|
|
Paris (www.aktiencheck.de) - Ouster-Aktienanalyse von BNP Paribas:
Egmond Haidt von BNP Paribas nimmt die Aktie des US-Herstellers von LiDAR-Sensoren und Sensortechnik Ouster Inc. (ISIN: US68989M2026, WKN: A3ECDT, Ticker-Symbol: 3Z7, NASDAQ-Symbol: OUST) unter die Lupe.
Eine heftige Berg- und Talfahrt habe die Ouster-Aktie in den vergangenen Wochen durchgemacht. [mehr]...
|
|
|
|
|
12.08.26 - 13:51
|
Schneider Electric Outperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Schneider Electric auf "Outperform" mit einem Kursziel von 330 Euro belassen. Die Zahl der Mechaniker, Elektriker und Schlosser begrenze das Tempo des Aufbaus von ......
|
|
|
12.08.26 - 13:33
|
InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 (Business Wire)
|
|
|
IDP-001 is a bispecific antibody-drug conjugate targeting EGFR and a novel Tumor-Associated Proximity Antigen identified through InduPro's proximity-guided platform
Phase 1 study is enrolling adults with advanced squamous non-small cell lung cancer and other solid tumors
Financing led by The Column Group, with participation from Vida Ventures, MRL Ventures Fund, Emerson Collective (advised by Yosemite), Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly and CompanySEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a $77 million Series B financing and the dosing of the first patient in the Phase 1 clinical study of IDP-001, the company's lead oncology program.
Proceeds from the financing will support Phase 1 clinical development and generation of early proof-of-concept data for IDP-001, as well as the adva...
|
|
|
|
|
|
|
12.08.26 - 12:24
|
Valneva Aktie: Borreliose-Impfstoff als großer Wachstumstreiber - Kursziel 12 Dollar (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Valneva-Aktienanalyse von TD Cowen:
Die Analysten von TD Cowen nehmen die Coverage für die Aktie von Valneva SE (ISIN: FR0004056851, WKN: A0MVJZ, Ticker-Symbol: AYJ, Euronext Paris-Symbol: VLA) mit dem Rating "buy" und dem Kursziel von 12 USD auf.
Das Basis-Impfstoffgeschäft des Unternehmens biete Schutz vor Abwärtsrisiken, während LB6V ein "risikoreduzierter" Lyme-Borreliose-Impfstoff sei, der durch eine validierte biologische Grundlage und die regulatorische Expertise von Pfizer gestützt werde, so TD Cowen in einer Research-Note. [mehr]...
|
|
|
|
Alle News zu Frankreich 8689.944 0.0% (CAC 40 Kurs)
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
